<DOC>
	<DOCNO>NCT00028418</DOCNO>
	<brief_summary>This dose-escalation study determine maximum tolerated dose toxic effect clofarabine patient chronic lymphocytic leukemia acute leukemia . Clofarabine synthesize hybrid nucleoside analog , believe possess good quality fludarabine chlorodeoxyadenosine , 2 active agent lymphoproliferative disorder . Thus , hop drug active less toxic similar drug .</brief_summary>
	<brief_title>Clofarabine Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>The first group patient treat start dose level 2 mg/m2 1 hour daily 5 day . Dosage escalation permit individual patient toxicity occur preceding course . Subsequent dose escalation 50 % Grade 2 toxicity , 35 % maximum tolerate dose . Completion date provide represent completion date grant per OOPD record</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<criteria>Inclusion criterion : Diagnosis chronic lymphocytic leukemia Diagnosis acute leukemia At least 2 week since prior chemotherapy , immunotherapy , and/or radiotherapy Recovered toxic effect prior therapy Bilirubin great 2 mg/dL Creatinine great 1.5 mg/dL Exclusion criterion : Candidate treatment high efficacy priority Pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2001</verification_date>
	<keyword>Acute Leukemia</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>Nucleosides</keyword>
	<keyword>Dose-Response Relationship , Drug</keyword>
	<keyword>Cladribine</keyword>
	<keyword>Fludarabine</keyword>
</DOC>